Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Korro Bio (KRRO) Accumulated Expenses (2019 - 2025)

Korro Bio's Accumulated Expenses history spans 7 years, with the latest figure at $1.8 million for Q4 2025.

  • For the quarter ending Q4 2025, Accumulated Expenses fell 50.01% year-over-year to $1.8 million, compared with a TTM value of $1.8 million through Dec 2025, down 50.01%, and an annual FY2025 reading of $1.8 million, down 50.01% over the prior year.
  • Accumulated Expenses for Q4 2025 was $1.8 million at Korro Bio, down from $3.3 million in the prior quarter.
  • The five-year high for Accumulated Expenses was $10.2 million in Q4 2023, with the low at $1.4 million in Q1 2021.
  • Average Accumulated Expenses over 5 years is $3.8 million, with a median of $3.3 million recorded in 2022.
  • Year-over-year, Accumulated Expenses soared 221.64% in 2023 and then crashed 63.84% in 2024.
  • Tracing KRRO's Accumulated Expenses over 5 years: stood at $4.4 million in 2021, then fell by 27.43% to $3.2 million in 2022, then soared by 221.64% to $10.2 million in 2023, then crashed by 63.84% to $3.7 million in 2024, then plummeted by 50.01% to $1.8 million in 2025.
  • Per Business Quant, the three most recent readings for KRRO's Accumulated Expenses are $1.8 million (Q4 2025), $3.3 million (Q3 2025), and $2.3 million (Q2 2025).